Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Amicus Therapeutics (FOLD) over the last 13 years, with Q3 2025 value amounting to $171.2 million.

  • Amicus Therapeutics' Accumulated Expenses rose 2574.94% to $171.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.2 million, marking a year-over-year increase of 2574.94%. This contributed to the annual value of $127.3 million for FY2024, which is 1174.74% down from last year.
  • Per Amicus Therapeutics' latest filing, its Accumulated Expenses stood at $171.2 million for Q3 2025, which was up 2574.94% from $145.1 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Accumulated Expenses registered a high of $171.2 million during Q3 2025, and its lowest value of $57.2 million during Q1 2021.
  • In the last 5 years, Amicus Therapeutics' Accumulated Expenses had a median value of $124.9 million in 2023 and averaged $114.5 million.
  • As far as peak fluctuations go, Amicus Therapeutics' Accumulated Expenses tumbled by 1913.28% in 2021, and later skyrocketed by 7285.0% in 2022.
  • Over the past 5 years, Amicus Therapeutics' Accumulated Expenses (Quarter) stood at $98.2 million in 2021, then decreased by 4.6% to $93.6 million in 2022, then soared by 54.05% to $144.2 million in 2023, then dropped by 11.75% to $127.3 million in 2024, then soared by 34.46% to $171.2 million in 2025.
  • Its Accumulated Expenses stands at $171.2 million for Q3 2025, versus $145.1 million for Q2 2025 and $129.9 million for Q1 2025.